ASX - By Stock
|
MSB |
Re:
Ann: CEO Presentation to 2020 Annual General Meeting
|
|
BarkingGecko
|
13 |
7.4K |
15 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
13
|
7.4K
|
15
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Trading halt
|
|
BarkingGecko
|
483 |
161K |
1 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
483
|
161K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
BarkingGecko
|
811 |
334K |
2 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
811
|
334K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
BarkingGecko
|
811 |
334K |
5 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
811
|
334K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
BarkingGecko
|
811 |
334K |
24 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
811
|
334K
|
24
|
|
ASX - By Stock
|
MSB |
Re:
TYPE A OUTCOME AND NOVARTIS PARTNERSHIP
|
|
BarkingGecko
|
111 |
55K |
27 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
111
|
55K
|
27
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
|
|
BarkingGecko
|
392 |
158K |
0 |
19/11/20 |
19/11/20 |
ASX - By Stock
|
392
|
158K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
|
|
BarkingGecko
|
392 |
158K |
2 |
18/11/20 |
18/11/20 |
ASX - By Stock
|
392
|
158K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
|
|
BarkingGecko
|
392 |
158K |
8 |
18/11/20 |
18/11/20 |
ASX - By Stock
|
392
|
158K
|
8
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit Nano and CEA-Leti broaden strategic partnership
|
|
BarkingGecko
|
133 |
33K |
6 |
17/11/20 |
17/11/20 |
ASX - By Stock
|
133
|
33K
|
6
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit Nano appoints Ilan Sever to drive R&D
|
|
BarkingGecko
|
75 |
26K |
1 |
16/11/20 |
16/11/20 |
ASX - By Stock
|
75
|
26K
|
1
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
BarkingGecko
|
10K |
3.6M |
1 |
13/11/20 |
13/11/20 |
ASX - By Stock
|
10K
|
3.6M
|
1
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
BarkingGecko
|
4.9K |
2.0M |
11 |
13/11/20 |
13/11/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
11
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
BarkingGecko
|
4.9K |
2.0M |
8 |
13/11/20 |
13/11/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
|
|
BarkingGecko
|
392 |
158K |
5 |
11/11/20 |
11/11/20 |
ASX - By Stock
|
392
|
158K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
MESO action tonight
|
|
BarkingGecko
|
3.1K |
1.4M |
1 |
11/11/20 |
11/11/20 |
ASX - By Stock
|
3.1K
|
1.4M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Pfizer announcement
|
|
BarkingGecko
|
127 |
41K |
5 |
10/11/20 |
10/11/20 |
ASX - By Stock
|
127
|
41K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Looking forward to the November short squeeze
|
|
BarkingGecko
|
106 |
36K |
1 |
06/11/20 |
06/11/20 |
ASX - By Stock
|
106
|
36K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Looking forward to the November short squeeze
|
|
BarkingGecko
|
106 |
36K |
6 |
06/11/20 |
06/11/20 |
ASX - By Stock
|
106
|
36K
|
6
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
BarkingGecko
|
10K |
3.6M |
10 |
06/11/20 |
06/11/20 |
ASX - By Stock
|
10K
|
3.6M
|
10
|
|
ASX - By Stock
|
WBT |
Re:
fair value
|
|
BarkingGecko
|
308 |
94K |
2 |
05/11/20 |
05/11/20 |
ASX - By Stock
|
308
|
94K
|
2
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
BarkingGecko
|
4.9K |
2.0M |
6 |
05/11/20 |
05/11/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
BarkingGecko
|
576 |
234K |
9 |
04/11/20 |
04/11/20 |
ASX - By Stock
|
576
|
234K
|
9
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
BarkingGecko
|
4.9K |
2.0M |
3 |
04/11/20 |
04/11/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
3
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
BarkingGecko
|
4.9K |
2.0M |
10 |
04/11/20 |
04/11/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
10
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
BarkingGecko
|
4.9K |
2.0M |
14 |
03/11/20 |
03/11/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
14
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
BarkingGecko
|
10K |
3.6M |
0 |
02/11/20 |
02/11/20 |
ASX - By Stock
|
10K
|
3.6M
|
0
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
BarkingGecko
|
10K |
3.6M |
0 |
02/11/20 |
02/11/20 |
ASX - By Stock
|
10K
|
3.6M
|
0
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
BarkingGecko
|
10K |
3.6M |
2 |
02/11/20 |
02/11/20 |
ASX - By Stock
|
10K
|
3.6M
|
2
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
BarkingGecko
|
4.9K |
2.0M |
3 |
02/11/20 |
02/11/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
3
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
BarkingGecko
|
4.9K |
2.0M |
11 |
28/10/20 |
28/10/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
11
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
BarkingGecko
|
10K |
3.6M |
5 |
28/10/20 |
28/10/20 |
ASX - By Stock
|
10K
|
3.6M
|
5
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
BarkingGecko
|
10K |
3.6M |
4 |
28/10/20 |
28/10/20 |
ASX - By Stock
|
10K
|
3.6M
|
4
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
BarkingGecko
|
4.9K |
2.0M |
23 |
28/10/20 |
28/10/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
23
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
BarkingGecko
|
10K |
3.6M |
2 |
28/10/20 |
28/10/20 |
ASX - By Stock
|
10K
|
3.6M
|
2
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
BarkingGecko
|
10K |
3.6M |
4 |
27/10/20 |
27/10/20 |
ASX - By Stock
|
10K
|
3.6M
|
4
|
|
ASX - By Stock
|
WBT |
Re:
fair value
|
|
BarkingGecko
|
308 |
94K |
3 |
26/10/20 |
26/10/20 |
ASX - By Stock
|
308
|
94K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
BarkingGecko
|
13K |
5.0M |
1 |
21/10/20 |
21/10/20 |
ASX - By Stock
|
13K
|
5.0M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Speculative 8-month target - $33.00 MSB for GVHD, COVID ARDS
|
|
BarkingGecko
|
139 |
95K |
2 |
19/10/20 |
19/10/20 |
ASX - By Stock
|
139
|
95K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Speculative 8-month target - $33.00 MSB for GVHD, COVID ARDS
|
|
BarkingGecko
|
139 |
95K |
2 |
19/10/20 |
19/10/20 |
ASX - By Stock
|
139
|
95K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
BarkingGecko
|
445 |
193K |
9 |
14/10/20 |
14/10/20 |
ASX - By Stock
|
445
|
193K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
BarkingGecko
|
445 |
193K |
2 |
14/10/20 |
14/10/20 |
ASX - By Stock
|
445
|
193K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Investigation of Mesoblast Limited (MESO) on Behalf of Investors
|
|
BarkingGecko
|
53 |
29K |
2 |
05/10/20 |
05/10/20 |
ASX - By Stock
|
53
|
29K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Investigation of Mesoblast Limited (MESO) on Behalf of Investors
|
|
BarkingGecko
|
53 |
29K |
15 |
05/10/20 |
05/10/20 |
ASX - By Stock
|
53
|
29K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
BarkingGecko
|
555 |
268K |
3 |
02/10/20 |
02/10/20 |
ASX - By Stock
|
555
|
268K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
BarkingGecko
|
555 |
268K |
12 |
02/10/20 |
02/10/20 |
ASX - By Stock
|
555
|
268K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
BarkingGecko
|
13K |
5.0M |
0 |
23/09/20 |
23/09/20 |
ASX - By Stock
|
13K
|
5.0M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Will the FDA refuse approval in the face of the favourable ODAC 9 versus 1 vote?
|
|
BarkingGecko
|
72 |
46K |
8 |
21/09/20 |
21/09/20 |
ASX - By Stock
|
72
|
46K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Will the FDA refuse approval in the face of the favourable ODAC 9 versus 1 vote?
|
|
BarkingGecko
|
72 |
46K |
4 |
21/09/20 |
21/09/20 |
ASX - By Stock
|
72
|
46K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
BarkingGecko
|
13K |
5.0M |
23 |
17/09/20 |
17/09/20 |
ASX - By Stock
|
13K
|
5.0M
|
23
|
|